- Clinical trial evaluating the Company's novel mRNA biomarkers demonstrated sensitivity for colorectal cancer of 94% with specificity of 97% and advanced adenoma sensitivity of 81%
- Pulsus Group's 4th International Conference on Gastroenterology, to be held in Paris, France, brings together world-renowned speakers to share discoveries and receive updates in the field of Gastroenterology
BERKELEY, Calif. and MAINZ, Germany, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) ("Mainz Biomed" or the "Company"), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today that it will present the positive detailed results from its ColoFuture study at the 4th International Conference on Gastroenterology which occurs on October 16th - 18th in Paris, France. The ColoFuture study was a multi-center international clinical trial assessing the potential to integrate a portfolio of novel gene expression (mRNA) biomarkers into ColoAlert®, the Company's highly efficacious, and easy-to-use screening test for colorectal cancer (CRC) being commercialized across Europe and in select international territories.
"The data generated from this study represents a potentially ground-breaking milestone for CRC detection and we are excited to share the details of our findings with the attending audience of international medical experts," commented Guido Baechler, Chief Executive Officer of Mainz Biomed. "Multiple novel mRNA biomarkers were identified for possible integration into our pivotal FDA PMA clinical trial, and we look forward to comparing ColoFuture's data outcome with results from our eAArly DETECT clinical study which remains on track to report in Q4 of this year."
Presentation Details:
Abstract | QC-ICGR23-128 |
Session |
Poster session, 4th International Conference of Gastroenterology, Paris, France |
Title | A novel and non-invasive mRNA and AI based early Colorectal Cancer and Advanced Adenoma detection approach - First interim data review of the international COLOFUTURE case control study |
Speaker | Dr. ... |